Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
3 pending office actions • 2 art units • 3 examiners • 0 of 3 (0%) have an AI response strategy ready
Gellycle Co. Ltd. operates a company patent portfolio in the Biotechnology & Pharmaceuticals technology area. The portfolio currently has 3 pending office actions, which are being reviewed by 3 distinct examiners. This distribution shows that each pending matter is being handled by a different official at the patent office. These 3 examiners are situated within 2 distinct art units, suggesting some overlap in the technical classification of the company's inventions.
The busiest examiner for the portfolio is MERCIER, MELISSA S, who has 1 busiest examiner pending office action. Since the total number of pending office actions is 3 and there are 3 distinct examiners, MERCIER, MELISSA S handles a portion of the active workload. The presence of 2 distinct art units indicates that the prosecution strategy must account for the specific nuances of different technical groups. Practitioners should focus on the individual requirements of the 3 distinct examiners to resolve the 3 pending office actions effectively. Coordinating responses across the 2 distinct art units will be necessary to maintain consistency.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 1 (33%) |
| §112 only | 1 (33%) |
| Multi-statute (no §101) | 1 (33%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| MERCIER, MELISSA S | 1 | 72.1% | +5.8% |
| BROOKS, KREGG T | 1 | 57.1% | +1.1% |
| ROGERS, JAMES WILLIAM | 1 | 46.2% | +22.3% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18875516 | CARRIER MATERIAL FOR LOCALLY RELEASING PARTICULATE SUBSTANCE | MERCIER, MELISSA S | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17922830 | HEMOSTATIC POLYMER MATERIAL KIT | ROGERS, JAMES WILLIAM | 35d overdue |
| Art Unit | Apps |
|---|---|
| 1615 | 1 |
| 1618 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18875516 | CARRIER MATERIAL FOR LOCALLY RELEASING PARTICULATE SUBSTANCE | MERCIER, MELISSA S | 1615 | §102§103§112 | Non-Final OA | — | Pending | Dec 16, 2024 |
| 18565147 | Polymer material with phase-separated structure obtained by controlling the number of branches | BROOKS, KREGG T | — | §112 | Non-Final OA | — | Pending | Nov 29, 2023 |
| 17922830 | HEMOSTATIC POLYMER MATERIAL KIT | ROGERS, JAMES WILLIAM | 1618 | §103 | Final Rejection | 35d overdue | Pending | Nov 02, 2022 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial